Navigation Links
ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
Date:7/9/2008

FREDERICK, Md., July 9 /PRNewswire/ -- ImQuest Life Sciences announced today the successful acquisition of funding from the National Institutes of Health to define the mechanism of action of their dual-acting pyrimidinedione HIV inhibitor IQP-0410. The objective of this one-year Small Business Innovative Research (SBIR) award will allow ImQuest scientist to further understand how the pyrimidinediones inhibit the replication of HIV. IQP-0410 has been determined to primarily inhibit the function of the virion reverse transcriptase, but the clinical candidate also possesses a novel second mechanism of action which functions to prevent the entry of HIV into human target cells, extends the range of action of the compound to HIV-2 and results in enhanced levels of activity against multi-drug resistant virus strains. The SBIR award will allow ImQuest to better define the putative entry inhibition target, thus allowing the eventual development of an entirely new class of virus entry inhibitors. Dr. Robert W. Buckheit, Jr., Dr. Todd Parsley, and Ms. Tracy Hartman lead the research project.

"We are extremely pleased to receive this NIH SBIR award," said Dr. Buckheit. "IQP-0410 represents a completely novel dual-acting chemotype for development as an HIV therapeutic and ImQuest hopes to more completely understand how this compound inhibits HIV replication, initiate our planned clinical trials, and work on the development of a new generation of even more potent entry inhibitors that will provide HIV-infected individuals with yet another therapeutic option to fight their disease."

ImQuest plans to submit an IND to the Food and Drug Administration in the third quarter of 2008 in order to initiate Phase 1 human clinical trials with IQP-0410. Preclinical pharmacology and toxicology results have been highly encouraging that the compound will present a new highly potent and less toxic alternative for primary and salvage therapies in HIV-infected individuals. The
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
(Date:7/28/2015)... , July 28, 2015 Seahorse Bioscience, ... metabolism, is the provider of XF Technology which ... disease research areas. As the links between mitochondrial ... cell metabolism is escalating rapidly.   ... the Nature Publishing Group (NPG) featuring XF Technology, ...
(Date:7/28/2015)... , July 28, 2015 Deerfield Management Company, ... Innovations Fund, L.P., which will invest in groundbreaking advancements ... genetic diseases, cancer, and orphan diseases. The venture capital ... how therapeutics are developed and improve the way healthcare ... of the largest healthcare-focused venture funds in the sector, ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... N.J., June 1 Today, BASF filed a lawsuit in ... against DuPont (E. l. du Pont de Nemours and Company) ... a key class of herbicides. Specifically, DuPont,s Optimum GAT corn ... component that enables successful tolerance toward an herbicide class known ...
... 1 Raptor Pharmaceuticals Corp. ("Raptor" or the ... it has dosed the first patient in its ... the University of California, San Diego ... ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a ...
... Presented at American Society of Clinical Oncology (ASCO) Meeting ... Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors - ... Therapeutics presented preliminary results of a Phase 1 clinical ... poster session at the 2009 Annual Meeting of the ...
Cached Biology Technology:BASF Sues DuPont for Patent Infringement 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... since Darwin, researchers have tried to explain the enormous ... at the University of Gothenburg, Sweden, are adding something ... so rich in tradition, by demonstrating how a bird ... years ago, Malte Andersson, a professor at the University ...
... April 28, 2010 In findings that could one day ... have described some striking differences between the biochemistry of stem ... Research Associate Professor Sheng Ding and Senior Director of the ... in an advance, online edition of the prestigious journal ...
... there is no known cause of autism, studies have ... the developmental brain disorder. New research has uncovered two ... Investigators will present their findings on Sunday, May 2 ... Vancouver, British Columbia, Canada. An estimated one in ...
Cached Biology News:Plumage-color traits more extreme over time 2Scripps Research team provides groundbreaking new understanding of stem cells 2Scripps Research team provides groundbreaking new understanding of stem cells 3Study adds to evidence that autism has genetic basis 2